From: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis
First Author and Year
Selection
Comparability
Exposure/Outcome
Total Score
Zhang 2022 [26]
****
**
***
*********
Ji 2023 [9]
Zhao 2023 [23]
